Discover
KTTA
Pasithea Therapeutics Corp.
0.57
2 x 0.42
2 x 0.66
bid
ask
+
0.05
9.99%
2 @ 06:00 AM
0.55 -0.01 (2.45%)
| Ytd | -56.05% | |
| 1y | -22.87% |
0.50
day range
0.61
0.28
52 week range
2.06
| Open | 0.50 | Prev Close | 0.52 | Low | 0.50 | High | 0.61 | Mkt Cap | 18.94M |
| Vol | 1.42M | Avg Vol | 862.61K | EPS | -1.42 | P/E | N/A | Forward P/E | -3.75 |
| Beta | 0.82 | Short Ratio | 0.32 | Inst. Own | 2.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-16 | 50-d Avg | 0.67 | 200-d Avg | 0.80 | 1yr Est | 2.00 |
KTTA News
benzinga.com
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Eva
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
globenewswire.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Lo
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, wit
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Bu
benzinga.com
Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibroma
-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and lo
benzinga.com
Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophi
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-